Cidofovir (Vistide)

An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.

Also Known As:

Vistide; 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine; 1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine; Cidofovir Anhydrous; Cidofovir Sodium; Cidofovir, (+-)-isomer; Cidofovir, (R)-isomer; Cidofovir, Sodium Salt; GS 504; GS-504; HPMPC; GS504; Phosphonic acid, (((1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-

Networked: 1086 relevant articles (210 outcomes, 124 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	De Clercq, Erik: 30 articles (12/2021 - 05/2002)
2.	Hostetler, Karl Y: 22 articles (01/2015 - 03/2003)
3.	Snoeck, Robert: 18 articles (04/2018 - 11/2002)
4.	Beadle, James R: 18 articles (01/2015 - 01/2004)
5.	Smee, Donald F: 18 articles (01/2015 - 05/2002)
6.	De Clercq, E: 17 articles (06/2007 - 02/2000)
7.	Snoeck, R: 15 articles (10/2018 - 02/2000)
8.	Kern, Earl R: 14 articles (12/2010 - 01/2003)
9.	Andrei, Graciela: 11 articles (04/2018 - 10/2006)
10.	Sidwell, Robert W: 11 articles (04/2008 - 05/2002)

Related Diseases

1.	Infections 05/12/2011 - "Of the compounds tested, topically applied cidofovir was the most effective treatment of cutaneous vaccinia virus infections in immunosuppressed mice. " 04/01/1991 - "The most remarkable feature of HPMPC was that a single administration of the compound, even as late as 4 days after infection, conferred significant protection against HSV-1 or HSV-2 infection. " 01/01/2015 - "To test infectivity of virus released from EPCs cultured in the presence of cidofovir, cell culture supernatants were used as inoculum for a further course of infection in UT7/EpoS1 cells, indicating a significant reduction in viral infectivity at 500 μM cidofovir. " 05/01/2004 - "Mean arterial oxygen saturation levels in these two cidofovir treatment groups were significantly higher than placebo on days 4 through 6 of the infection, indicating an improvement in lung function. " 04/01/1991 - "HPMPC was also effective against intraperitoneal HSV infection if it was given orally at a dose of 50 mg/kg/day or higher. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 03/01/1999 - "PML is a terrifying neurological complication which has been resistant to a number of drugs, but cidofovir is currently being studied in an AIDS Clinical Trials Group (ACTG 363) and a European study group; results to date are controversial. " 01/01/2019 - "A case of an atypical resistant granulomatous HSV-1 and HSV-2 ulceration in an AIDS patient treated with intralesional cidofovir." 05/01/2008 - "For AIDS patients with PML or failing non-AIDS patients with neurologic deterioration, cidofovir can be considered. " 03/01/2002 - "Intravenous cidofovir, in the absence of contra-indications, should be considered as part of this aggressive therapeutic approach, especially in patients with AIDS in whom the prognosis is particularly poor." 10/22/2001 - "Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome."
3.	Retinitis 11/01/1999 - "Cidofovir has proved to be highly effective in treatment of CMV retinitis. " 05/01/1997 - "Intravitreal cidofovir has been shown to be a long acting and highly efficacious treatment for CMV retinitis; however decrease in IOP is an adverse effect. " 01/01/1996 - "Two company studies suggest cidofovir is effective against CMV retinitis progression. " 07/28/2000 - "Although effective for the treatment of CMV retinitis, cidofovir has potential toxicity. " 12/01/1996 - "FDA grants marketing clearance of Vistide for the treatment of CMV retinitis."
4.	Papilloma (Papillomatosis) 04/01/2000 - "We conclude that intralesional cidofovir appears to be a promising new treatment for controlling--and perhaps at higher dosages curing--refractory laryngeal papillomas, while causing little or no injury to laryngeal structures." 03/01/2010 - "Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse." 07/01/2008 - "Although results of case series suggest that cidofovir may decrease the frequency and rapidity of papilloma regrowth, no blinded placebo-controlled studies have demonstrated efficacy. " 03/01/2008 - "The purpose of this study was to evaluate the efficacy of cidofovir injection following initial papilloma excision with a microdebrider. " 04/01/2002 - "An open-trial prospective evaluation of the efficacy of intralesional cidofovir in subjects with laryngeal papilloma. "
5.	Recurrent respiratory papillomatosis 01/01/2012 - "Intralesional cidofovir appears to be effective in the treatment of recurrent respiratory papillomatosis, although further studies are required to determine its safety." 11/01/2010 - "The efficacy of cidofovir in juvenile recurrent respiratory papillomatosis (JRRP) remains uncertain due to the lack of published case-control studies. " 11/01/2010 - "Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis." 07/01/2006 - "To investigate the efficacy of intralesional cidofovir in the treatment of recurrent respiratory papillomatosis (RRP) in children. " 12/01/2004 - "To evaluate the efficacy of intralesional cidofovir injection for the treatment of recurrent respiratory papillomatosis (RRP). "

Related Drugs and Biologics

1.	Cidofovir (Vistide)
2.	Antiviral Agents (Antivirals)
3.	Foscarnet
4.	Ganciclovir (Cytovene)
5.	Nucleosides
6.	Acyclovir (Aciclovir)
7.	Organophosphonates (Phosphonates)
8.	brincidofovir
9.	tecovirimat
10.	adefovir

Related Therapies and Procedures

1.	Therapeutics
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Injections
4.	Intralesional Injections
5.	Liver Transplantation